Join the Oncology Voice Network. Join for Free
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
VoicesOfOncology ForbesBooks OncologyExperts CancerInnovation PharmaLeadership BiotechVoices AccelerateCancerCures OncologyCommunity CancerResearch HealthcareCollaboration LifeSciencesLeadership OncologyInsights FutureOfOncology ClinicalDevel

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes


Share This Article


We are proud to announce the forthcoming publication of Voices of Oncology — a first-of-its-kind collection of expert perspectives from across the oncology ecosystem, arriving July 2025 in partnership with Forbes Books.

Co-edited by Dr. Kirk V. Shepard, MD and Dr. Ramin Farhood, PharmD, MBA, Voices of Oncology gathers the insights of more than 30 influential leaders in oncology drug development, clinical research, advocacy, and healthcare innovation. These contributors represent the full spectrum of cancer care — from biotech pioneers and pharmaceutical strategists to academic researchers and patient-focused advocates.

More than just a book, Voices of Oncology is a movement — one driven by the urgent need to break down silos and foster collaboration across functions, companies, and stakeholder groups. Its goal: to accelerate access to innovation and improve outcomes for people facing cancer.

Each chapter in Voices of Oncology offers not only deep expertise, but also a candid look at the systemic challenges — and untapped opportunities — that shape the future of cancer treatment. The publication invites readers into real-world case studies, cross-sector strategies, and future-forward ideas that aim to reshape the way we approach oncology innovation.

 

Why This Matters

Cancer remains one of the most complex and dynamic challenges in healthcare. The pace of scientific progress is extraordinary — yet access to that innovation remains uneven, fragmented, and often hindered by organizational and communication barriers.

Voices of Oncology addresses this head-on. It amplifies the lived experience and thought leadership of those working at the heart of this field. It creates common ground — a platform where pharma, providers, regulators, and patients can align their efforts and accelerate impact.

 

Coming July 2025

As the inaugural release in a new series of collaborative publications, Voices of Oncology sets the tone for what’s next: a more connected, transparent, and purpose-driven future for oncology.

Stay tuned for pre-order details, exclusive contributor highlights, and community discussions leading up to the July 2025 launch.

 

To those already working tirelessly to improve the cancer care landscape — this book is for you.

To those looking to join the conversation — we welcome your voice.

Voices of Oncology book, Forbes oncology publication, cancer innovation insights, oncology expert perspectives, oncology thought leadership 2025, cancer drug development leaders, cross-functional oncology collaboration, accelerating cancer cures, oncology

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Press Release
Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard
OVN Avatar OVN Staff

Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN